BTZ-N3 Azide Substituent Combats Mycobacterium Tuberculosis Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-tuberculosis agents face challenges due to the emergence of multi-drug resistant and extensively drug resistant strains of Mycobacterium tuberculosis, necessitating the development of new compounds that effectively target the DprE1 enzyme without the limitations of existing nitroaromatic compounds.
Innovation Solution
Design and synthesis of 1,3-benzothiazinone azide (BTZ-N3) compounds with an electrophilic azide substituent, which bind to the same pocket as BTZ043 but exhibit ambident electrophilic properties, potentially activating through alternative mechanisms to inhibit DprE1, and are evaluated for their in vitro activity against M. tuberculosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nitroaromatic compounds (BTZ043) are used to target DprE1 enzyme, then anti-TB activity is achieved, but drug resistance emerges due to limited mechanistic diversity
Solution Approach 1:
The patent changes the chemical parameter from nitro group to azide group at the 4-position of 1,3-benzothiazinone, transforming BTZ043 into BTZ-N3. This parameter change creates a fundamentally different electrophilic mechanism (ambident azide vs. nitro reduction) while maintaining target binding, thereby achieving both reliable anti-TB activity and mechanistic diversity to combat drug resistance
Solution Approach 2:
The invention creates a composite molecular structure combining the 1,3-benzothiazinone scaffold with an azide substituent. This composite approach integrates the known pharmacophore (benzothiazinone core that binds DprE1) with a novel electrophilic warhead (azide group), producing a compound that maintains target affinity while introducing new reactivity patterns for enhanced adaptability against resistant strains
2Adaptability or versatility
If new electrophilic compounds (BTZ-N3) are synthesized to combat drug resistance, then mechanistic diversity is improved, but development time and complexity increase
Solution Approach 1:
The patent employs preliminary action by designing BTZ-N3 based on the known structure-activity relationship of BTZ043. The 1,3-benzothiazinone scaffold and its binding mode to DprE1 were already established, allowing the inventors to pre-optimze the core structure before introducing the novel azide group. This preliminary groundwork significantly reduced development time compared to de novo drug design
Solution Approach 2:
The molecular design is segmented into two functional parts: the 1,3-benzothiazinone scaffold (responsible for target binding and pharmacokinetics) and the azide substituent (responsible for electrophilic reactivity). This segmentation allows independent optimization of each component - the scaffold can be refined based on existing knowledge while the azide group provides the desired mechanistic diversity, streamlining the overall development process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
BTZ-N3 demonstrates impressive activity against the H37Rv strain of M. tuberculosis, comparable to standard drugs, and its unique biochemical reactivity supports its potential as a new anti-tuberculosis agent, highlighting the importance of the benzothiazinone scaffold and electron-withdrawing character.
Implementation Method 1
it was shown to involve the reductive activation of the nitro group into a nitroso intermediate
Data Source
AI summary
A compound, having the following formula:or resonance form thereof, or salt thereof, or salt of resonance form thereof is provided, wherein E includes an electrophilic site, and wherein R1-R4 and n are defined herein. Compositions and methods including the compound are also provided.